Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer
Conditions
Interventions
Docetaxel, Reolysin and Prednisone
Docetaxel and Prednisone
Locations
11
Canada
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
BCCA - Abbotsford Centre
Abbotsford British Columbia, British Columbia, Canada
BCCA - Cancer Centre for the Southern Interior
Kelowna, British Columbia, Canada
BCCA - Fraser Valley Cancer Centre
Surrey, British Columbia, Canada
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Start Date
December 14, 2012
Primary Completion Date
April 26, 2016
Completion Date
May 20, 2016
Last Updated
August 4, 2023
NCT06594926
NCT06844383
NCT06487507
NCT05919264
NCT07004582
NCT06257264
Lead Sponsor
Canadian Cancer Trials Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions